XBIO (Xenetic Bio) Forward P/E Multiple

Official company branding of Xenetic Biosciences, Inc. (XBIO)

Developing oncology platforms requires colossal investment and faces intense pressure from pharma behemoths, where any regulatory delays are critical. Xenetic Biosciences (XBIO) addresses these challenges with XCART, an innovative foundation for creating personalized T-cell therapy. The company's 12-month forward P/E, where 0.00 shows the value of this parameter, illustrates the market valuation of the prospects for drugs combating B-cell lymphomas.

xeneticbio.com - XBIO Forward P/E Multiple (period 07/04/2022 - 11/18/2026)

Summary analytical data breakdowns for Xenetic Biosciences, Inc. (XBIO)

- current price and projected stock value:
Summary company analytics:Xenetic Biosciences, Inc.
Brand item of xeneticbio.com

When assessing the investment attractiveness of Xenetic Biosciences (XBIO), it is essential to weigh the business's market value against its profit generation potential. By analyzing the company's forward P/E ratio, an investor can determine the premium paid for future earnings, which in this case are supported by stable royalties from the use of the patented PolyXen technology, thereby revealing the fair value of capital.

Competitors of Xenetic Biosciences (XBIO)

Forward P/E Multiple ONC|HALO (Halozyme Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple RVMD (revmed.com)|AAPG - Projected Price to Earnings|CGON: Projected Price to Earnings|URGN - Forward P/E Multiple|Bicara Bio (BCAX) - Future Price to Earnings|Personalis Corp - Future Price to Earnings Multiple|ERAS (Erasca Inc) - Forward P/E Multiple|Projected Price to Earnings Ratio Delcath Systems, Inc. DCTH|Projected Price to Earnings YMAB (Y-mAbs Corp)|Forward P/E Multiple Aura Bio (AURA)|Forward P/E Multiple CADL (Candel Therapeutics Inc.)|ARAY - Projected Price to Earnings|SLS - Future Price to Earnings|Actuate Therapeutics - Market Cap to Future Earnings Ratio|CTOR: Forward P/E Multiple|TuHURA (HURA) - Forward P/E Multiple|TARA (Protara Therapeutics Inc) - Forward P/E Multiple|FATE: Future Price to Earnings Multiple|Forward P/E Multiple WHWK|TCRX (TScan) - Future Price to Earnings Multiple|Future Price to Earnings Champions Oncology, Inc. CSBR|XBIT - Projected Price to Earnings|CEL-SCI - Forward P/E Multiple|OSTX - Forward P/E Multiple|Radiopharm Theranostics Limited (RADX) - Future Price to Earnings|ARTV - Market Cap to Projected Earnings|Projected Price to Earnings ANL|Future Price to Earnings VERU|Forward P/E Multiple TPST|XLO: Price to Expected Earnings Ratio|Forward P/E Multiple RENB (Renovaro Inc.)|Mural Bio (MURA) - Projected Price to Earnings Ratio|Kairos Pharma Ltd - Forward P/E Multiple|Price to Expected Earnings Ratio OKUR|CytoMed Therapeutics Limited (GDTC) - Future Price to Earnings|CRIS - Market Cap to Projected Earnings|Projected Price to Earnings APLM|Tharimmune (THAR) - Market Cap to Projected Earnings|Projected Price to Earnings ADVB (Advanced Biomed Inc.)|Genprex - Price to Future Earnings Ratio|Forward P/E Multiple CLDI (Calidi Biotherapeutics, Inc.)|SBFM - Projected Price to Earnings|SLRX: Projected Price to Earnings|Purple Biotech - Market Cap to Future Earnings Ratio|American Oncology Network (AONC) - Future Price to Earnings|Price to Future Earnings Ratio BGNE|Projected Price to Earnings CKPT|Future Price to Earnings ELEV|Forward P/E Multiple ICAD|Forward P/E Multiple Ikena Oncology Inc. (IKNA)|Forward P/E Multiple NTBL (Notable Labs Ltd)|Market Cap to Projected Earnings Viracta Therapeutics (VIRX)|MOR: Projected Price to Earnings|NAYA (NAYA Bio) - Price to Future Earnings Ratio|AAPGV: Forward P/E Multiple